Drug Trial Radar · NCT04640480
Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors
Last checked: Nov 19, 2026Latest source record: Jan 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
21
Actual
Start
Oct 21, 2020
Primary completion
Jan 5, 2026
Study completion Jan 5, 2026
Sponsor
- Lead sponsor
- SN BioScienceIndustry
- Sponsor type
- Industry
- First posted
- Nov 23, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
SNB-101 is a novel nano-particle formulation of SN-38, the active metabolite of irinotecan(CPT-11). Study SNB101P01 is a multicenter, open-label, dose escalation, phase 1 study of SNB 101 with its active ingredient SN-38, in participants with advanced solid tumors. Dose escalation will occur using a modified accelerated titration design (ATD). All participants will receive SNB 101 in different cohorts. SNB 101 will be administered intravenously to participants on day 1 and day 15 of each 28 day treatment cycle until progressive disease, unacceptable toxicity, death, or withdrawal of consent, whichever occurs first. A Safety Review Committee will determine dose escalation, de-escalation, and modification and the MTD/RP2D based on DLTs and other safety information.
Conditions
- Colorectal Cancer
- Breast Cancer
- Pancreas Cancer
- Ovarian Cancer
- Small-cell Lung Cancer
- Gastric Cancer
- Head and Neck Cancer
Interventions
SNB-101Drug
SN-38 dosage ranges from 1 to 7 will be determined by Safety Review Committee meeting
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicity(DLT)Time frame: up to 18 months(depending on safety variable)
- Permanent discontinuation of SNB-101 and dose reduction due to adverse events(AEs)Time frame: up to 18 months(depending on safety variable)
- Number of participants with clinically meaningful changes in Laboratory test results from baselineTime frame: up to 18 months(depending on safety variable)
- Number of participants with clinically meaningful changes in Vital signs from baselineTime frame: up to 18 months(depending on safety variable)
- Electrocardiogram(ECG) resultsTime frame: up to 18 months(depending on safety variable)
- Number of clinically significant Chest radiograph findings(chest x-ray, CXR)Time frame: up to 18 months(depending on safety variable)
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
CHA Medical Center
Seongnam-si, Gyeonggi-do, South Korea
The Severance Hospital of the Yonsei University
Seoul, Seoul, South Korea
The Catholic University of Korea Seoul ST. Mary's Hospital
Seoul, Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.